Author

John S. Grundy

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD: RESULTS FROM A PHASE 1 DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEERS
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD: RESULTS FROM A PHASE 1 DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEERS

John S. Grundy  et al.

MODEL-PREDICTED LYMPHOCYTE RESPONSE AND RECOVERY PROFILES FOR THE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS OZANIMOD AND ETRASIMOD
MODEL-PREDICTED LYMPHOCYTE RESPONSE AND RECOVERY PROFILES FOR THE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS OZANIMOD AND ETRASIMOD

John S. Grundy  et al.

A PHASE 1 DRUG INTERACTION STUDY EVALUATING THE EFFECTS OF ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD IN HEALTHY VOLUNTEERS
A PHASE 1 DRUG INTERACTION STUDY EVALUATING THE EFFECTS OF ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD IN HEALTHY VOLUNTEERS

John S. Grundy  et al.

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

John S. Grundy  et al.

Item 1 - 4 / 4
1